Group 1 - Oruka Therapeutics, Inc. (ORKA) shares have increased by 42.7% in the past four weeks, closing at $27.44, with a mean price target of $44.89 indicating a potential upside of 63.6% [1] - The average price target from nine analysts ranges from a low of $26.00 to a high of $60.00, with a standard deviation of $9.82, suggesting variability in estimates [2] - Analysts show strong agreement on ORKA's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for ORKA has increased by 1.1% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - ORKA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Tamboran Resources Corporation (TBN) has seen a 25.8% increase in share price over the past four weeks, closing at $26.61, with a potential upside of 42.8% based on Wall Street analysts' mean price target of $38 [1]. Price Targets - The average price target consists of five estimates ranging from a low of $32.00 to a high of $42.00, with a standard deviation of $3.94, indicating a potential increase of 20.3% to 57.8% from the current price level [2]. - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a useful indicator for investors [2][9]. Analyst Sentiment - Analysts show strong agreement on TBN's ability to report better earnings than previously predicted, which supports the view of potential upside [4]. - The Zacks Consensus Estimate for the current year has increased by 3.2% over the past month, with no negative revisions, indicating positive sentiment among analysts [12]. Zacks Rank - TBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which further indicates potential upside in the near term [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction implied by these targets appears to be a good guide for potential price movement [14].

Core Viewpoint - Shares of Amylyx Pharmaceuticals, Inc. (AMLX) have increased by 3.6% over the past four weeks, closing at $14.31, with a potential upside indicated by Wall Street analysts' mean price target of $18.5, suggesting a 29.3% increase [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.85, where the lowest estimate is $12.00 (indicating a 16.1% decline) and the highest is $25.00 (indicating a 74.7% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about AMLX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 8.8% over the past month, with two estimates increasing and no negative revisions [12] Zacks Rank and Investment Potential - AMLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for potential investment [14]

Core Viewpoint - Cognizant (CTSH) shows potential for significant upside, with a mean price target of $85.5 indicating a 25.7% increase from the current price of $68.03 [1] Price Targets and Analyst Estimates - The mean estimate consists of 20 short-term price targets, with a standard deviation of $8.79, indicating variability among analysts [2] - The lowest estimate is $70.00, suggesting a 2.9% increase, while the highest estimate is $103.00, indicating a potential surge of 51.4% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding price movement direction [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CTSH's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with one estimate moving higher and no negative revisions [12] - CTSH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Dutch Bros (BROS) shares have increased by 7.1% in the past four weeks, closing at $57.14, with a potential upside of 38.9% based on Wall Street analysts' mean price target of $79.38 [1][4]. Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets with a standard deviation of $8.48, indicating variability among analysts [2]. - The lowest estimate is $65.00, suggesting a 13.8% increase, while the highest estimate is $95.00, indicating a potential surge of 66.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about BROS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, one estimate has increased, leading to a 0.7% rise in the Zacks Consensus Estimate [12]. - BROS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10]. - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8].

Core Viewpoint - Orla Mining Ltd. (ORLA) shows potential for significant upside, with a mean price target of $16.31 indicating a 49% increase from its current price of $10.95 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.98, suggesting a range of estimates from $12.89 (17.7% increase) to $19.95 (82.2% increase) [2][4]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Revisions - Analysts have shown increasing optimism about ORLA's earnings, with four estimates revised higher in the last 30 days and no negative revisions, leading to a 17.2% increase in the Zacks Consensus Estimate [12][11]. - The correlation between earnings estimate revisions and near-term stock price movements supports the expectation of an upside in ORLA's stock [11]. Zacks Rank and Investment Potential - ORLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14].

Core Viewpoint - Elastic (ESTC) shares have shown a slight increase of 0.2% over the past month, closing at $86.07, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $118.33, representing a 37.5% upside [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 24 short-term price targets with a standard deviation of $15.52, where the lowest estimate is $90.00 (4.6% increase) and the highest is $150.00 (74.3% increase) [2]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ESTC's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - The Zacks Consensus Estimate for the current year has risen by 27.5% over the past month, with six estimates increasing and no negative revisions [12]. - ESTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. Caution on Price Targets - While consensus price targets are a popular metric, relying solely on them for investment decisions may not be prudent due to historical concerns about analysts' biases and inflated targets [3][8][10].

Core Viewpoint - Castle Biosciences, Inc. (CSTL) shows potential for significant upside, with a mean price target of $35.63 indicating a 50.1% increase from the current price of $23.74 [1] Price Targets - The average price target consists of eight estimates ranging from $30.00 to $41.00, with a standard deviation of $3.54, suggesting a consensus among analysts [2] - The lowest estimate indicates a 26.4% increase, while the highest suggests a 72.7% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts have shown increasing optimism about CSTL's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 1.5% rise in the Zacks Consensus Estimate [12] Zacks Rank - CSTL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not reliably indicate the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Knightscope, Inc. (KSCP) shows significant upside potential with a mean price target of $15.67, indicating a 170.2% increase from the current trading price of $5.8 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $10.02, where the lowest estimate is $8.00 (37.9% increase) and the highest is $27.00 (365.5% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about KSCP's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.5% over the past month, with one estimate increasing and no negative revisions [12] - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, and reliance solely on them may not yield favorable returns [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Disc Medicine, Inc. (IRON) has shown a significant price increase of 38.6% over the past four weeks, with a mean price target of $108.82 indicating a potential upside of 26.3% from the current trading price of $86.17 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $18.55, suggesting variability in analyst predictions. The lowest estimate is $86.00 (0.2% decline), while the highest is $153.00 (77.6% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about IRON's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with one estimate moving higher and no negative revisions [12] - IRON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for near-term upside [13] Caution on Price Targets - While consensus price targets are often sought after, they can mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]